BioCentury
ARTICLE | Clinical News

Prima posts big gain on CVac's survival trend

May 21, 2015 1:56 AM UTC

Prima BioMed Ltd. (ASX:PRR; NASDAQ:PBMD) surged $4.31 (269%) to $5.91 on NASDAQ on Wednesday after reporting final subset analyses from a Phase II ovarian cancer trial that missed its primary progression-free survival (PFS) endpoint in 2013. In the additional analysis, Prima said its CVac cancer vaccine led to a "clinically meaningful" trend toward improving overall survival among second remission patients in the trial.

The company said median overall survival had not yet been reached after 42 months among second remission patients in the treatment group, compared to 25.5 months for second remission patients receiving SOC of observation only (HR=0.17; 95% CI: 0.02, 1.44; p=0.07). ...